TRX 319
Alternative Names: TRX-319Latest Information Update: 28 May 2024
At a glance
- Originator Tr1X
- Class CAR-T cell therapies; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Regulatory T-lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Autoimmune disorders
Most Recent Events
- 29 Apr 2024 Preclinical trials in Autoimmune disorders in USA (Parenteral) (Tr1x Bio Pipeline, April 2024)